Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib and Arsenic Trioxide in EGFR-TKI Resistant NSCLC
NCT02066870Phase 1Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Jan 2014
- Primary completion
- Sep 2015
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of arsenic trioxide in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Primary endpoint: Number of Participants with Serious and Non-Serious Adverse Events up to 8 weeks. Status: unknown.
02
Drugs
arsenic trioxide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02066870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02066870.